Literature DB >> 26767035

Role of systemic inflammation scores in pulmonary metastasectomy for colorectal cancer.

Tommaso Claudio Mineo1, Federico Tacconi1.   

Abstract

BACKGROUND: Patients with pulmonary metastases from colorectal cancer can benefit from surgical removal. However, the biological determinants of postsurgical outcome are not completely elucidated. We evaluated the role of host systemic inflammation status in this setting.
METHODS: The modified Glasgow prognostic score (based on serum C-reactive protein and albumin levels) and the neutrophil-to-lymphocyte (NTL) ratio were obtained from 44 patients who received curative-intent metastasectomy, and were used as indicators of systemic inflammation status. We tested the impact of both of these parameters on overall survival (OS) and progression-free survival (PFS), as well as their correlation with other well-known prognosticators.
RESULTS: Five-year PFS and OS rates were 18% and 49%, respectively. At univariate analysis, multiple metastases, disease-free interval <36 months, and a Glasgow score of 2 (P = 0.031) were significantly associated to a worse PFS rate. A NTL ratio >3 predicted disease progression in the short-term (P = 0.036), but the effect on late events was weaker (P = 0.079). Factors associated with worse OS were multiple metastasis (P = 0.002), elevated carcinoembryonic antigen (P = 0.009), a Glasgow score of 2 (P = 0.029), and a faster metastasis growth (P = 0.008). At Cox regression analysis, neither a Glasgow score of 2, nor elevated NTL ratio showed an independent effect on survival rates.
CONCLUSIONS: Systemic inflammation scores did not perform well as independent survival prognosticators in patients undergoing curative-intent pulmonary metastasectomy. Further investigation is warranted to evaluate whether these measurements could still be useful when restricting the analysis to specific patient subcategories or to diverse postoperative phases.

Entities:  

Keywords:  Albumin; C-reactive protein; colorectal cancer; neutrophil-to-lymphocyte ratio; pulmonary metastasectomy

Year:  2014        PMID: 26767035      PMCID: PMC4704369          DOI: 10.1111/1759-7714.12114

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  36 in total

1.  [Resection of lung metastases: long-term results and prognostic analysis based on 5206 cases--the International Registry of Lung Metastases].

Authors:  G Friedel; U Pastorino; M Buyse; R J Ginsberg; P Girard; P Goldstraw; M Johnston; P McCormack; H Pass; J B Putnam; H Toomes
Journal:  Zentralbl Chir       Date:  1999       Impact factor: 0.942

2.  Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies.

Authors:  Johann Dréanic; Marianne Maillet; Marion Dhooge; Olivier Mir; Catherine Brezault; François Goldwasser; Stanislas Chaussade; Romain Coriat
Journal:  Med Oncol       Date:  2013-07-10       Impact factor: 3.064

3.  More than one pulmonary resections or combined lung-liver resection in 79 patients with metastatic colorectal carcinoma.

Authors:  Jose R Jarabo; Elena Fernández; Joaquín Calatayud; Ana M Gómez; Cristina Fernández; Antonio J Torres; Florentino Hernando
Journal:  J Surg Oncol       Date:  2011-06-28       Impact factor: 3.454

4.  Biology of colorectal pulmonary metastasis: implications for surgical resection.

Authors:  Michael Poullis; John Littler; John Gosney
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-11-23

5.  Pulmonary metastasectomy for colorectal cancer: long-term survival and prognostic factors.

Authors:  R N Younes; F Abrao; J Gross
Journal:  Int J Surg       Date:  2013-01-19       Impact factor: 6.071

Review 6.  Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma.

Authors:  Masayoshi Inoue; Mitsunori Ohta; Keiji Iuchi; Akihide Matsumura; Kan Ideguchi; Tsutomu Yasumitsu; Katsuhiro Nakagawa; Kenjiro Fukuhara; Hajime Maeda; Shin-ichi Takeda; Masato Minami; Yuko Ohno; Hikaru Matsuda
Journal:  Ann Thorac Surg       Date:  2004-07       Impact factor: 4.330

7.  A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer.

Authors:  Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Eiji Noda; Hiroshi Ohtani; Yukio Nishiguchi; Kosei Hirakawa
Journal:  Anticancer Res       Date:  2013-08       Impact factor: 2.480

8.  Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer.

Authors:  K Watanabe; K Nagai; A Kobayashi; M Sugito; N Saito
Journal:  Br J Surg       Date:  2009-09       Impact factor: 6.939

9.  Elevated C-reactive protein is associated with the tumor depth of invasion but not with disease recurrence in stage II and III colorectal cancer.

Authors:  Takaaki Fujii; Reina Yajima; Yuichi Tabe; Satoru Yamaguchi; Soichi Tsutsumi; Takayuki Asao; Hiroyuki Kuwano
Journal:  Hepatogastroenterology       Date:  2013-09

10.  Evaluation of preoperative C-reactive protein aids in predicting poor survival in patients with curative colorectal cancer with poor lymph node assessment.

Authors:  Yuji Toiyama; Hiroyuki Fujikawa; Yuki Koike; Susumu Saigusa; Yasuhiro Inoue; Koji Tanaka; Yasuhiko Mohri; Chikao Miki; Masato Kusunoki
Journal:  Oncol Lett       Date:  2013-04-16       Impact factor: 2.967

View more
  3 in total

1.  Uniportal video-assisted thoracic surgery colorectal lung metastasectomy in non-intubated anesthesia.

Authors:  Vincenzo Ambrogi; Francesco Sellitri; Gianluca Perroni; Orazio Schillaci; Tommaso Claudio Mineo
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

2.  Uniportal non-intubated lung metastasectomy.

Authors:  Tommaso Claudio Mineo; Francesco Sellitri; Eleonora Fabbi; Vincenzo Ambrogi
Journal:  J Vis Surg       Date:  2017-09-14

3.  Immunological and Inflammatory Impact of Non-Intubated Lung Metastasectomy.

Authors:  Tommaso Claudio Mineo; Francesco Sellitri; Gianluca Vanni; Filippo Tommaso Gallina; Vincenzo Ambrogi
Journal:  Int J Mol Sci       Date:  2017-07-07       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.